Patients diagnosed with T1GSCC from 1999 to 2020 were identified from a public database. Clinical, demographic, and social data were extracted. Treatment and patient groups and subgroups were compared with log-rank test, Cox proportional test, and propensity-score matched (PSM).
Eight hundred and eighty-eight patients with T1GSCC were included in the study, with a median follow-up of 61 months. The 5- and 10-year overall survival (OS) S versus RT were 76% versus 71% and 60% versus 52% (p = 0.02), respectively. In the subgroup analysis, S was associated with better OS for T1b, male, and public service patients (p < 0.05). In the PSM cohort of S versus RT with 110 patients each, there was no significant difference in the OS, CSS, and LC.
T1GSCC has favorable outcomes with S or RT.
方法:从公共数据库中确定了1999年至2020年诊断为T1GSCC的患者。临床,人口统计学,并提取了社会数据。治疗与患者组和亚组进行比较,采用对数秩检验,Cox比例试验,和倾向得分匹配(PSM)。
结果:本研究纳入了88例T1GSCC患者,中位随访时间为61个月。5年和10年总生存率(OS)S与RT分别为76%对71%和60%对52%(p=0.02),分别。在亚组分析中,S与T1b的更好操作系统相关,男性,和公共服务患者(p<0.05)。在S与RT的PSM队列中,每组110例患者,操作系统没有显著差异,CSS,LC。
结论:T1GSCC与S或RT具有良好的结局。